1. Home
  2. SBR vs ABCL Comparison

SBR vs ABCL Comparison

Compare SBR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$75.10

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.41

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
ABCL
Founded
1982
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
3.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SBR
ABCL
Price
$75.10
$11.41
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.40
AVG Volume (30 Days)
23.4K
5.2M
Earning Date
05-14-2026
05-11-2026
Dividend Yield
6.41%
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
$12.77
N/A
Revenue Growth
N/A
160.56
52 Week Low
$65.31
$2.75
52 Week High
$84.39
$12.58

Technical Indicators

Market Signals
Indicator
SBR
ABCL
Relative Strength Index (RSI) 48.51 56.96
Support Level $72.58 $10.44
Resistance Level $76.59 $12.58
Average True Range (ATR) 1.46 0.65
MACD -0.05 -0.27
Stochastic Oscillator 28.37 37.61

Price Performance

Historical Comparison
SBR
ABCL

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: